A forgotten alternative: Bromides for refractory status epilepticus.

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Pharmacology

Background:

• Infantile epilepsy syndromes, such as malignant migrating partial epilepsy of infancy (MMPEI) and Ohtahara syndrome (OS), often present with severe, refractory status epilepticus.
• Standard antiepileptic drugs (AEDs) frequently fail to control seizures in these challenging pediatric cases.

Observation:

• Two infants, one with MMPEI and another with OS, experienced severe refractory status epilepticus.
• Both infants had failed to respond to multiple conventional AEDs.

Findings:

• Treatment with potassium bromide (KBr) resulted in a significant reduction in seizure frequency and duration in both patients.
• Dosage augmentation of KBr was safely managed, leading to positive clinical outcomes.
• No apparent adverse effects were observed during KBr treatment.

Implications:

• Potassium bromide demonstrates significant efficacy and safety as a therapeutic option for infants with severe intractable seizures refractory to other AEDs.
• This study supports considering KBr as a valuable treatment strategy in pediatric epilepsy when conventional therapies are insufficient.
• Further research into KBr's role in managing refractory infantile epilepsy is warranted.